- Home
- MCTR vs ADVM Comparison
MCTR vs ADVM Comparison
Compare MCTR & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCTR
- ADVM
- Stock Information
- Founded
- MCTR 2014
- ADVM 2006
- Country
- MCTR Hong Kong
- ADVM United States
- Employees
- MCTR N/A
- ADVM N/A
- Industry
- MCTR
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MCTR
- ADVM Health Care
- Exchange
- MCTR NYSE
- ADVM Nasdaq
- Market Cap
- MCTR 91.8M
- ADVM 98.0M
- IPO Year
- MCTR 2025
- ADVM 2014
- Fundamental
- Price
- MCTR $7.51
- ADVM $2.93
- Analyst Decision
- MCTR
- ADVM Strong Buy
- Analyst Count
- MCTR 0
- ADVM 6
- Target Price
- MCTR N/A
- ADVM $25.83
- AVG Volume (30 Days)
- MCTR 27.2K
- ADVM 176.5K
- Earning Date
- MCTR 01-01-0001
- ADVM 04-15-2025
- Dividend Yield
- MCTR N/A
- ADVM N/A
- EPS Growth
- MCTR N/A
- ADVM N/A
- EPS
- MCTR 0.00
- ADVM N/A
- Revenue
- MCTR $4,453,234.00
- ADVM $1,000,000.00
- Revenue This Year
- MCTR N/A
- ADVM $1,187.80
- Revenue Next Year
- MCTR N/A
- ADVM N/A
- P/E Ratio
- MCTR $6,137.65
- ADVM N/A
- Revenue Growth
- MCTR N/A
- ADVM N/A
- 52 Week Low
- MCTR $3.76
- ADVM $2.89
- 52 Week High
- MCTR $12.00
- ADVM $11.87
- Technical
- Relative Strength Index (RSI)
- MCTR N/A
- ADVM 31.79
- Support Level
- MCTR N/A
- ADVM $3.07
- Resistance Level
- MCTR N/A
- ADVM $3.71
- Average True Range (ATR)
- MCTR 0.00
- ADVM 0.46
- MACD
- MCTR 0.00
- ADVM -0.12
- Stochastic Oscillator
- MCTR 0.00
- ADVM 9.20
About MCTR CTRL GROUP LTD
CTRL Group Ltd is an integrated marketing and advertising services provider in Hong Kong specializing in mobile games promotion for the local market. It provide services to mobile game developers, principally developers of mobile gaming applications or apps that gamers download from the developers' websites and applicable mobile operating systems, such as Apple Store or Android Google Play Store.
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.